Runquan is interested in exploring the interactions between chemokines and chemokine receptors during various critical pathological conditions. Based on this aim, she chooses CXCR4 agonism and CCR5 antagonism as two important targets of study, with respective significances in novel therapeutics for central nervous system (CNS) diseases and acquired immune deficiency syndrome (AIDS), in order of providing better insights of the structural mechanisms for distinct functions of chemokine receptors, and facilitating the development of novel strategies for therapeutic interventions of related diseases.